Related Experiment Videos
Lack of antiinflammatory activity of metronidazole
Abstract:
Metronidazole was given to rats with experimentally induced inflammation to evaluate whether the drug has any antiinflammatory effect. Inflammation was caused by injection of Freund's complete adjuvant into a paw. The oedema of the paw measured on the 4th day was not influenced after metronidazole 20 mg/kg/day or 160 mg/kg/day, whereas phenylbutazone 80 mg/kg/day significantly decreased the volume of the paw. The concentration of orosomucoid did not differ in the group of rats given metronidazole 20 mg/kg/day as compared to the control group. However, the orosomucoid concentration was lower in the group given metronidazole 160 mg/kg/day, as was the case in the phenylbutazone group. In groups of rats with polyarthritis studied on the 14th and 21st day there was no difference of arthritic index, volume of paw or orosomucoid concentration in neither low nor high dose metronidazole as compared to the control groups. The phenylbutazone groups, however, showed a lower arthritic index, lower volume of paw and lower orosomucoid concentration.
Insights
Metronidazole did not demonstrate anti-inflammatory effects in rats with induced paw edema or polyarthritis. Phenylbutazone, however, significantly reduced inflammation and orosomucoid levels, indicating its anti-inflammatory properties.
Area of Science:
- Pharmacology
- Inflammation Research
- Drug Efficacy Studies
Background:
- Inflammation is a complex biological response.
- Metronidazole is an antibiotic with a debated anti-inflammatory role.
- Orosomucoid is an acute-phase protein often elevated during inflammation.
Purpose of the Study:
- To investigate the anti-inflammatory potential of metronidazole.
- To compare metronidazole's effects with phenylbutazone, a known anti-inflammatory drug.
- To assess changes in paw edema, arthritic index, and orosomucoid concentration.
Main Methods:
- Experimentally induced paw inflammation and polyarthritis in rats using Freund's complete adjuvant.
- Administration of varying doses of metronidazole (20 mg/kg/day and 160 mg/kg/day).
- Administration of phenylbutazone (80 mg/kg/day) as a positive control.
- Measurement of paw volume, arthritic index, and serum orosomucoid concentration at different time points.
Main Results:
- Metronidazole did not significantly reduce paw edema or arthritic index at any dose.
- High-dose metronidazole (160 mg/kg/day) showed a trend towards lowering orosomucoid levels, similar to phenylbutazone.
- Phenylbutazone significantly decreased paw edema, arthritic index, and orosomucoid concentration compared to controls.
Conclusions:
- Metronidazole lacks significant anti-inflammatory activity in rat models of acute paw inflammation and chronic polyarthritis.
- The observed effect on orosomucoid levels at high metronidazole doses warrants further investigation but does not confirm anti-inflammatory action.
- Phenylbutazone confirmed its efficacy as a potent anti-inflammatory agent in the studied models.